-
9 killed in Canada mass shooting that targeted school, residence: police
-
De Zerbi leaves Marseille 'by mutual agreement'
-
Netanyahu to push Trump on Iran missiles in White House talks
-
England captain Stokes has surgery after being hit in face by ball
-
Rennie, Joseph lead running to become next All Blacks coach
-
Asian stock markets mixed as traders weigh US data, await jobs
-
Australian Olympic snowboarder airlifted to hospital with broken neck
-
Moderna says US refusing to review mRNA-based flu shot
-
Instagram boss to testify at social media addiction trial
-
'Artists of steel': Japanese swords forge new fanbase
-
New York model, carved in a basement, goes on display
-
Noisy humans harm birds and affect breeding success: study
-
More American women holding multiple jobs as high costs sting
-
Charcoal or solar panels? A tale of two Cubas
-
Several wounded in clashes at Albania opposition rally
-
Chelsea's draw with Leeds 'bitter pill' for Rosenior
-
'On autopilot': US skate star Malinin nears more Olympic gold
-
Carrick frustrated by Man Utd's lack of sharpness in West Ham draw
-
Frank confident of keeping Spurs job despite Newcastle defeat
-
James's All-NBA streak ends as Lakers rule superstar out of Spurs clash
-
Anti-Khamenei slogans in Tehran on eve of revolution anniversary: social media footage
-
YouTube says it is not social media in landmark addiction trial
-
Colombian senator kidnapped, president targeted in election run-up
-
Britney Spears sells rights to her music catalog: US media
-
West Ham end Man Utd's winning run, Spurs sink to 16th
-
US skate star Malinin leads after short programme in Olympics
-
Man Utd's Sesko strikes late to rescue West Ham draw
-
Shiffrin flops at Winter Olympics as helmet row grows
-
Celtics' Tatum practices with G League team but injury return uncertain
-
Gisele Pelicot publishes memoirs after rape trial ordeal
-
Newcastle beat sorry Spurs to leave Frank on the brink
-
'Outrage' as LGBTQ Pride flag removed from Stonewall monument
-
Chappell Roan leaves agency headed by embattled 2028 Olympic chief
-
Venezuelan authorities move Machado ally to house arrest
-
YouTube rejects addiction claims in landmark social media trial
-
Google turns to century-long debt to build AI
-
'I felt guided by them': US skater Naumov remembers parents at Olympics
-
Till death do us bark: Brazilian state lets pets be buried with owners
-
Ukrainian athlete vows to wear banned helmet at Winter Olympics
-
'Confident' Pakistan ready for India blockbuster after USA win
-
Latam-GPT: a Latin American AI to combat US-centric bias
-
Gauff dumped out of Qatar Open, Swiatek, Rybakina through
-
Paris officers accused of beating black producer to stand trial in November
-
Istanbul bars rock bands accused of 'satanism'
-
Olympic bronze medal biathlete confesses affair on live TV
-
US commerce chief admits Epstein Island lunch but denies closer ties
-
Mayor of Ecuador's biggest city arrested for money laundering
-
Farhan, spinners lead Pakistan to easy USA win in T20 World Cup
-
Stocks mixed as muted US retail sales spur caution
-
Macron wants more EU joint borrowing: Could it happen?
Moderna says US refusing to review mRNA-based flu shot
Vaccine manufacturer Moderna said Tuesday the US Food and Drug Administration was refusing to review an application for its first mRNA-based flu shot.
The move comes as the current iteration of the FDA has called for a reconsideration of approval procedures for certain vaccines, including for influenza -- proposed federal policy changes under President Donald Trump that have triggered widespread alarm among public health and medical professionals.
Moderna, a US company, said the agency's top vaccine regulator, Vinay Prasad, wrote in a letter that Moderna's clinical trial was not "adequate and well-controlled," and had not tested its experimental shot against the best product on the market.
In the large trial Moderna had compared its new vaccine with Fluarix, an approved flu shot from the company GSK.
Moderna said the rejection was "inconsistent with previous written communications" with the FDA branch that regulates biological products, including vaccines, known by the acronym CBER.
The decision "did not identify any safety or efficacy concerns with our product" and "does not further our shared goal of enhancing America's leadership in developing innovative medicines," Moderna CEO Stephane Bancel said in the statement.
"It should not be controversial to conduct a comprehensive review of a flu vaccine submission that uses an FDA-approved vaccine as a comparator in a study that was discussed and agreed on with CBER prior to starting."
Moderna said it had received a Refusal-to-File letter, which would indicate the application did not meet the requirements for substantive review. The company said it had requested a meeting to discuss the decision.
The letter did not identify any safety or efficacy concerns regarding the mRNA vaccine, said Moderna, which added the shot was accepted for review in the European Union, Canada and Australia.
During his first term Trump called mRNA technology a "modern-day miracle."
It was used during the Covid-19 pandemic to swiftly develop an immunization against the fast-spreading illness, and was credited with saving millions of lives.
Vaccines against Covid-19 are considered safe and effective by global health authorities, and protect against the most severe forms of the infection.
But in his second term, Trump has appointed Robert F. Kennedy Jr as his health chief, and the long-time vocal vaccine skeptic has spent the past year reshaping federal health agencies in his image.
That has meant spreading false information and sowing doubt about the safety and efficacy of vaccines widely known to be safe, and upending the pediatric immunization schedule.
Notably, Kennedy cut off federal research grants that funded mRNA development.
X.Habash--SF-PST